Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Repurchased
Ratios

Xeris Biopharma Holdings (XERS) Long-Term Debt Issuances: 2020-2024

  • Xeris Biopharma Holdings' Long-Term Debt Issuances was N/A to $50.0 million in Q1 2024 from the same period last year, while for Mar 2024 it was $199.7 million, marking a year-over-year change of. This contributed to the annual value of $50.0 million for FY2024, which is N/A change from last year.
  • Latest data reveals that Xeris Biopharma Holdings reported Long-Term Debt Issuances of $50.0 million as of Q1 2024, which was up 2.21% from $48.9 million recorded in Q4 2022.
  • Xeris Biopharma Holdings' 5-year Long-Term Debt Issuances high stood at $97.3 million for Q1 2022, and its period low was $3.5 million during Q4 2020.
  • Its 2-year average for Long-Term Debt Issuances is $65.4 million, with a median of $50.0 million in 2024.